文献リスト

1）Marshall RP, Puddicombe A, Cookson WO, et al. Adult familial cryptogenic fibrosing alveolitis in the United Kingdom. Thorax. 2000; 55: 143-6

2）Nogee LM, Dunbar AE 3rd, Wert SE, et al. A mutation in the surfactant protein C gene associated with familial interstitial lung disease. N Engl J Med. 2001; 344: 573-9

3）Thomas AQ, Lane K, Phillips J 3rd, et al. Heterozygosity for a surfactant protein C gene mutation associated with usual interstitial pneumonitis and cellular nonspecific interstitial pneumonitis in one kindred. Am J Respir Crit Care Med. 2002; 165: 1322-8

4）Shulenin S, Nogee LM, Annilo T, et al. ABCA3 gene mutations in newborns with fatal surfactant deficiency. N Engl J Med. 2004; 350: 1296-303

5）Bullard JE, Wert SE, Whitsett JA, et al. ABCA3 mutations associated with pediatric interstitial lung disease. Am J Respir Crit Care Med. 2005; 172: 1026-31

6）Young LR, Nogee LM, Barnett B, et al. Usual interstitial pneumonia in an adolescent with ABCA3 mutations. Chest. 2008; 134: 192-5

7）Yokota T, Matsumura Y, Ban N, et al. Heterozygous ABCA3 mutation associated with non-fatal evolution of respiratory distress. Eur J Pediatr. 2008; 167: 691-3

8）Kitazawa H, Moriya K, Niizuma H, et al. Interstitial lung disease in two brothers with novel compound heterozygous ABCA3 mutations. Eur J Pediatr. 2013; 172: 953-7

9）Nogee LM, de Mello DE, Dehner LP, et al. Brief report: deficiency of pulmonary surfactant protein B in congenital alveolar proteinosis. N Engl J Med. 1993; 328: 406-10

10）Nogee LM, Garnier G, Dietz HC, et al. A mutation in the surfactant protein B gene responsible for fatal neonatal respiratory disease in multiple kindreds. J Clin Invest. 1994; 93: 1860-3

11）Suzuki T, Sakagami T, Rubin BK, et al. Familial pulmonary alveolar proteinosis caused by mutations in CSF2RA. J Exp Med. 2008; 205: 2703-10

12）Tanaka T, Motoi N, Tsuchihashi Y, et al. Adult-onset hereditary pulmonary alveolar proteinosis caused by a single-base deletion in CSF2RB. J Med Genet. 2011; 48: 205-9

13）Suzuki T, Maranda B, Sakagami T, et al. Hereditary pulmonary alveolar proteinosis caused by recessive CSF2RB mutations. Eur Respir J. 2011; 37: 201-4

14）Drachtman RA, Alter BP. Dyskeratosis congenita. Dermatol Clin. 1999; 13: 33-9

15）Dokal I. Dyskeratosis congenita in all its forms. Br J Haematol. 2000; 110: 768-79

16）Calado RT, Young NS. Telomere diseases. N Engl J Med. 2009; 361: 2353-65

17）Vulliamy T, Marrone A, Szydlo R, et al. Disease anticipation is associated with progressive telomere shortening in families with dyskeratosis congenita due to mutations in TERC. Nat Genet. 2004; 36: 447-9

18）Armanios M, Chen JL, Chang YP, et al. Haploinsufficiency of telomerase reverse transcriptase leads to anticipation in autosomal dominant dyskeratosis congenita. Proc Natl Acad Sci U S A . 2005; 102: 15960-4

19）Parry EM, Alder JK, Lee SS, et al. Decreased dyskerin levels as a mechanism of telomere shortening in X-linked dyskeratosis congenita. J Med Genet. 2011; 48: 327-33

20）Safa WF, Lestringant GG, Frossard PM. X-linked dyskeratosis congenita: restrictive pulmonary disease and a novel mutation. Thorax. 2001; 56: 891-4

21）Giri N, Lee R, Faro A, et al. Lung transplantation for pulmonary fibrosis in dyskeratosis congenita: case report and systematic literature review. BMC Blood Disord. 2011; 11: 3

22）Marrone A, Sokhal P, Walne A, et al. Functional characterization of novel telomerase RNA (TERC) mutations in patients with diverse clinical and pathological presentations. Haematologica. 2007; 92: 1013-20

23）Burkhalter JL, Morano JU, McCay MB. Diffuse interstitial lung disease in neurofibromatosis. South Med J. 1986; 79: 944-6

24）Massaro D, Katz S. Fibrosing alveolitis: its occurrence, roentgenographic, and pathologic features in von Recklinghausen’s neurofibromatosis. Am Rev Respir Dis. 1996; 93: 934-42

25）Webb WR, Goodman PC. Fibrosing alveolitis in patients with neurofibromatosis. Radiology. 1977; 122: 289-93

26）Hermansky F, Pudlak P. Albinism associated with hemorrhagic diathesis and unusual pigmented reticular cells in the bone marrow: report of two cases with histochemical studies. Blood. 1959; 14: 162-9

27）Gahl WA, Brantly M, Kaiser-Kupfer MI, et al. Genetic defects and clinical characteristics of patients with a form of oculocutaneous albinism (Hermansky-Pudlak syndrome). N Engl J Med. 1998; 338: 1258-64

28）Brantly M, Avila NA, Shotelersuk V, et al. Pulmonary function and high-resolution CT findings in patients with an inherited form of pulmonary fibrosis, Hermansky-Pudlak syndrome, due to mutations in HPS-1. Chest. 2000; 117: 129-36

29）Dell’Angelica EC, Shotelersuk V, Aguilar RC, et al. Altered trafficking of lysosomal proteins in Hermansky-Pudlak syndrome due to mutations in the beta 3A subunit of the AP-3 adaptor. Mol Cell. 1999; 3: 11-21

30）Morgan NV, Pasha S, Johnson CA, et al. A germline mutation in BLOC1S3/reduced pigmentation causes a novel variant of Hermansky-Pudlak syndrome (HPS8). Am J Hum Genet. 2006; 78: 160-6

31）Martina JA, Moriyama K, Bonifacino JS. BLOC-3, a protein complex containing the Hermansky-Pudlak syndrome gene products HPS1 and HPS4. J Biol Chem. 2003; 278: 29376-84

32）Suzuki T, Li W, Zhang Q, et al. The gene mutated in cocoa mice, carrying a defect of organelle biogenesis, is a homologue of the human Hermansky-Pudlak syndrome-3 gene. Genomics. 2001; 78: 30-7

33）Zhang Q, Zhao B, Li W, et al. Ru2 and Ru encode mouse orthologs of the genes mutated in human Hermansky-Pudlak syndrome types 5 and 6. Nat Genet. 2003; 33: 145-53

34）Li W, Zhang Q, Oiso N, et al. Hermansky-Pudlak syndrome type 7 (HPS-7) results from mutant dysbindin, a member of the biogenesis of lysosome-related organelles complex 1 (BLOC-1). Nat Genet. 2003; 35: 84-9

35）Avila NA, Brantly M, Premkumar A, et al. Hermansky-Pudlak syndrome: radiography and CT of the chest compared with pulmonary function tests and genetic studies. AJR Am J Roentgenol. 2002; 179: 887-92

36）Anderson PD, Huizing M, Claassen DA, et al. Hermansky-Pudlak syndrome type 4 (HPS-4): clinical and molecular characteristics. Hum Genet. 2003; 113: 10-7

37）Bachli EB, Brack T, Eppler E, et al. Hermansky-Pudlak syndrome type 4 in a patient from Sri Lanka with pulmonary fibrosis. Am J Med Genet A. 2004; 127A: 201-7

38）Gahl WA, Brantly M, Troendle J, et al. Effect of pirfenidone on the pulmonary fibrosis of Hermansky-Pudlak syndrome. Mol Genet Metab. 2002; 76: 234-42

39）Nakatani Y, Nakamura N, Sano J, et al. Interstitial pneumonia in Hermansky-Pudlak syndrome: significance of florid foamy swelling/degeneration (giant lamellar body degeneration) of type-2 pneumocytes. Virchows Arch. 2000; 437: 304-13

40）Lyerla TA, Rusiniak ME, Borchers M, et al. Aberrant lung structure, composition, and function in a murine model of Hermansky-Pudlak syndrome. Am J Physiol Lung Cell Mol Physiol. 2003; 285: L643-53

41）Mahavadi P, Korfei M, Henneke I, et al. Epithelial stress and apoptosis underlie Hermansky- Pudlak syndrome-associated interstitial pneumonia. Am J Respir Crit Care Med. 2010; 182: 207-19

42）Kerem E, Elstein D, Abrahamov A, et al. Pulmonary function abnormalities in type I Gaucher disease. Eur Respir J. 1996; 9: 340-5

43）Miller A, Brown LK, Pastores GM, et al. Pulmonary involvement in type 1 Gaucher disease: functional and exercise findings in patients with and without clinical interstitial lung disease. Clin Genet. 2003; 63: 368-76

44）Goitein O, Elstein D, Abrahamov A, et al. Lung involvement and enzyme replacement therapy in Gaucher’s disease. QJM. 2001; 94: 407-15

45）McGovern MM, Wasserstein MP, Giugliani R, et al. A prospective, cross-sectional survey study of the natural history of Niemann-Pick disease type B. Pediatrics. 2008; 122: e341-9

46）Mendelson DS, Wasserstein MP, Desnick RJ, et al. Type B Niemann-Pick disease: findings at chest radiography, thin-section CT, and pulmonary function testing. Radiology. 2006; 238: 339-45

47）Parto K, Svedstrom E, Majurin ML, et al. Pulmonary manifestations in lysinuric protein intolerance. Chest. 1993; 104: 1176-82

48）Deutsch GH, Young LR, Deterding RR, et al. Diffuse lung disease in young children: application of a novel classification scheme. Am J Respir Crit Care Med. 2007; 176: 1120-8

49）Nogee LM. Genetic Basis of Children’s Interstitial Lung Disease. Pediatr Allergy Immunol Pulmonol. 2010; 23: 15-24

50）Wert SE, Whitsett JA, Nogee LM. Genetic disorders of surfactant dysfunction. Pediatr Dev Pathol. 2009; 12: 253-74

51）Andersen C, Ramsay JA, Nogee LM, et al. Recurrent familial neonatal deaths: hereditary surfactant protein B deficiency. Am J Perinatol. 2000; 17: 219-24

52）Somaschini M, Wert S, Mangili G, et al. Hereditary surfactant protein B deficiency resulting from a novel mutation. Intensive Care Med. 2000; 26: 97-100

53）Wegner DJ, Hertzberg T, Heins HB, et al. A major deletion in the surfactant protein-B gene causing lethal respiratory distress. Acta Paediatr. 2007; 96: 516-20

54）Dunbar AE 3rd, Wert SE, Ikegami M, et al. Prolonged survival in hereditary surfactant protein B (SP-B) deficiency associated with a novel splicing mutation. Pediatr Res. 2000; 48: 275-82

55）Ballard PL, Nogee LM, Beers MF, et al. Partial deficiency of surfactant protein B in an infant with chronic lung disease. Pediatrics. 1995; 96: 1046-52

56）Cameron HS, Somaschini M, Carrera P, et al. A common mutation in the surfactant protein C gene associated with lung disease. J Pediatr. 2005; 146: 370-5

57）van Moorsel CH, van Oosterhout MF, Barlo NP, et al. Surfactant protein C mutations are the basis of a significant portion of adult familial pulmonary fibrosis in a dutch cohort. Am J Respir Crit Care Med. 2010; 182: 1419-25

58）Guillot L, Epaud R, Thouvenin G, et al. New surfactant protein C gene mutations associated with diffuse lung disease. J Med Genet. 2009; 46: 490-4

59）Bullard JE, Nogee LM. Heterozygosity for ABCA3 mutations modifies the severity of lung disease associated with a surfactant protein C gene (SFTPC) mutation. Pediatr Res. 2007; 62: 176-9

60）Lawson WE, Grant SW, Ambrosini V, et al. Genetic mutations in surfactant protein C are a rare cause of sporadic cases of IPF. Thorax. 2004; 59: 977-80

61）Markart P, Ruppert C, Wygrecka M, et al. Surfactant protein C mutations in sporadic forms of idiopathic interstitial pneumonias. Eur Respir J. 2007; 29: 134-7

62）Bridges JP, Wert SE, Nogee LM, et al. Expression of a human surfactant protein C mutation associated with interstitial lung disease disrupts lung development in transgenic mice. J Biol Chem. 2003; 278: 52739-46

63）Mulugeta S, Nguyen V, Russo SJ, et al. A surfactant protein C precursor protein BRICHOS domain mutation causes endoplasmic reticulum stress, proteasome dysfunction, and caspase 3 activation. Am J Respir Cell Mol Biol. 2005; 32: 521-30

64）Mulugeta S, Maguire JA, Newitt JL, et al. Misfolded BRICHOS SP-C mutant proteins induce apoptosis via caspase-4- and cytochrome c-related mechanisms. Am J Physiol Lung Cell Mol Physiol. 2007; 293: L720-9

65）Lawson WE, Cheng DS, Degryse AL, et al. Endoplasmic reticulum stress enhances fibrotic remodeling in the lungs. Proc Natl Acad Sci U S A. 2011; 108: 10562-7

66）Ono S, Tanaka T, Ishida M, et al. Surfactant protein C G100S mutation causes familial pulmonary fibrosis in Japanese kindred. Eur Respir J. 2011; 38: 861-9

67）Rosen DM, Waltz DA. Hydroxychloroquine and surfactant protein C deficiency. N Engl J Med. 2005; 352: 207-8

68）Nakajima F, Aratani S, Fujita H, et al. Synoviolin inhibitor LS-102 reduces endoplasmic reticulum stress-induced collagen secretion in an in vitro model of stress-related interstitial pneumonia. Int J Mol Med. 2015; 35: 110-6

69）Serrano AG, Perez-Gil J. Protein-lipid interactions and surface activity in the pulmonary surfactant system. Chem Phys Lipids. 2006; 141: 105-18

70）Mulugeta S, Gray JM, Notarfrancesco KL, et al. Identification of LBM180, a lamellar body limiting membrane protein of alveolar type II cells, as the ABC transporter protein ABCA3. J Biol Chem. 2002; 277: 22147-55

71）Cheong N, Madesh M, Gonzales LW, et al. Functional and trafficking defects in ATP binding cassette A3 mutants associated with respiratory distress syndrome. J Biol Chem. 2006; 281: 9791-800

72）Ban N, Matsubara Y, Sakai H, et al. ABCA3 as a Lipid transporter in pulmonary surfactant biogenesis. J Biol Chem. 2007; 282: 9628-34

73）Matsumura Y, Ban N, Ueda K, et al. Characterization and classification of ATP-binding cassette transporter ABCA3 mutants in fatal surfactant deficiency. J Biol Chem. 2007; 281: 34503-14

74）Bullard JE, Wert SE, Whitsett JA, et al. ABCA3 mutations associated with pediatric interstitial lung disease. Am J Respir Crit Care Med. 2005; 172: 1026-31

75）Young LR, Nogee LM, Barnett B, et al. Usual interstitial pneumonia in an adolescent with ABCA3 mutations. Chest. 2008; 134: 192-5

76）Yokota T, Matsumura Y, Ban N, et al. Heterozygous ABCA3 mutation associated with non-fatal evolution of respiratory distress. Eur J Pediatr. 2008; 167: 691-3

77）Kitazawa H, Moriya K, Niizuma H, et al. Interstitial lung disease in two brothers with novel compound heterozygous ABCA3 mutations. Eur J Pediatr. 2013; 172: 953-7

78）Trapnell BC, Whitsett JA, Nakata K. Pulmonary alveolar proteinosis. N Engl J Med. 2003; 349: 2527-39

79）Suzuki T, Sakagami T, Rubin BK, et al. Familial pulmonary alveolar proteinosis caused by mutations in CSF2RA. J Exp Med. 2008; 205: 2703-10

80）Tanaka T, Motoi N, Tsuchihashi Y, et al. Adult-onset hereditary pulmonary alveolar proteinosis caused by a single-base deletion in CSF2RB. J Med Genet. 2011; 48: 205-9

81）Suzuki T, Sakagami T, Young LR, et al. Hereditary pulmonary alveolar proteinosis: pathogenesis, presentation, diagnosis, and therapy. Am J Respir Crit Care Med. 2010; 182: 1292-304

82）Steele MP, Speer MC, Loyd JE, et al. Clinical and pathologic features of familial interstitial pneumonia. Am J Respir Crit Care Med. 2005; 172: 1146-52

83）Seibold MA, Wise AL, Speer MC, et al. A common MUC5B promoter polymorphism and pulmonary fibrosis. N Engl J Med. 2011; 364: 1503-12

84）Armanios MY, Chen JJ, Cogan JD, et al. Telomerase mutations in families with idiopathic pulmonary fibrosis. N Engl J Med. 2007; 356: 1317-26

85）Tsakiri KD, Cronkhite JT, Kuan PJ, et al. Adult-onset pulmonary fibrosis caused by mutations in telomerase. Proc Natl Acad Sci U S A. 2007; 104: 7552-7

86）Cronkhite JT, Xing C, Raghu G, et al. Telomere shortening in familial and sporadic pulmonary fibrosis. Am J Respir Crit Care Med. 2008; 178: 729-37

87）Diaz de Leon A, Cronkhite JT, Katzenstein AL, et al. Telomere lengths, pulmonary fibrosis and telomerase (TERT) mutations. PLoS One. 2010; 5: e10680

88）Wang Y, Kuan PJ, Xing C, et al. Genetic defects in surfactant protein A2 are associated with pulmonary fibrosis and lung cancer. Am J Hum Genet. 2009; 84: 52-9

89）Maitra M, Wang Y, Gerard RD, et al. Surfactant protein A2 mutations associated with pulmonary fibrosis lead to protein instability and endoplasmic reticulum stress. J Biol Chem. 2010; 285: 22103-13

90）Sosman MC, Dodd GD, Jones WD, et al. The familial occurrence of pulmonary alveolar microlithiasis. Am J Roentgenol Radium Ther Nucl Med. 1957; 77: 947-1012

91）Ucan ES, Keyf AI, Aydilek R, et al. Pulmonary alveolar microlithiasis: review of Turkish reports. Thorax. 1993; 48: 171-3

92）Castellana G, Lamorgese V. Pulmonary alveolar microlithiasis. World cases and review of the literature. Respiration. 2003; 70: 549-55

93）Corut A, Senyigit A, Ugur SA, et al. Mutations in SLC34A2 cause pulmonary alveolar microlithiasis and are possibly associated with testicular microlithiasis. Am J Hum Genet. 2006; 79: 650-6

94）Huqun, Izumi S, Miyazawa H, et al. Mutations in the SLC34A2 gene are associated with pulmonary alveolar microlithiasis. Am J Respir Crit Care Med. 2007; 175: 263-8

95）Suzuki T, Mayhew C, Sallese A, et al. Use of induced pluripotent stem cells to recapitulate pulmonary alveolar proteinosis pathogenesis. Am J Respir Crit Care Med. 2014; 189: 183-93

96）Suzuki T, Arumugam P, Sakagami T, et al. Pulmonary macrophage transplantation therapy. Nature. 2014; 514: 450-4

NPO医学中央雑誌刊行会 https://www.jamas.or.jp/ info@jamas.or.jp